Patient Research Partner, EULAR, Amsterdam, The Netherlands
Saint George Hospital University Medical Center, Beirut, Lebanon.
Ann Rheum Dis. 2024 Oct 21;83(11):1443-1453. doi: 10.1136/ard-2024-225566.
Since the publication of the 2011 European Alliance of Associations for Rheumatology (EULAR) recommendations for patient research partner (PRP) involvement in rheumatology research, the role of PRPs has evolved considerably. Therefore, an update of the 2011 recommendations was deemed necessary.
In accordance with the EULAR Standardised Operational Procedures, a task force comprising 13 researchers, 2 health professionals and 10 PRPs was convened. The process included an online task force meeting, a systematic literature review and an in-person second task force meeting to formulate overarching principles (OAPs) and recommendations. The level of agreement of task force members was assessed anonymously (0-10 scale).
The task force developed five new OAPs, updated seven existing recommendations and formulated three new recommendations. The OAPs address the definition of a PRP, the contribution of PRPs, the role of informal caregivers, the added value of PRPs and the importance of trust and communication in collaborative research efforts. The recommendations address the research type and phases of PRP involvement, the recommended number of PRPs per project, the support necessary for PRPs, training of PRPs and acknowledgement of PRP contributions. New recommendations concern the benefits of support and guidance for researchers, the need for regular evaluation of the patient-researcher collaboration and the role of a designated coordinator to facilitate collaboration. Agreements within the task force were high and ranged between 9.16 and 9.96.
The updated EULAR recommendations for PRP involvement are more substantially based on evidence. Together with added OAPs, they should serve as a guide for researchers and PRPs and will ultimately strengthen the involvement of PRPs in rheumatology research.
自 2011 年欧洲风湿病联盟(EULAR)发布关于患者研究伙伴(PRP)参与风湿病研究的建议以来,PRP 的角色发生了很大变化。因此,有必要更新 2011 年的建议。
按照 EULAR 标准化操作程序,召集了一个由 13 名研究人员、2 名卫生专业人员和 10 名 PRP 组成的工作组。该过程包括一次在线工作组会议、一次系统的文献回顾和一次现场第二次工作组会议,以制定总体原则(OAP)和建议。工作组成员的一致性匿名评估(0-10 分)。
工作组制定了五个新的 OAP,更新了七个现有的建议,并制定了三个新的建议。OAP 涉及 PRP 的定义、PRP 的贡献、非正式照顾者的角色、PRP 的附加值以及信任和沟通在合作研究中的重要性。建议涉及 PRP 参与的研究类型和阶段、每个项目推荐的 PRP 数量、PRP 所需的支持、PRP 的培训和 PRP 贡献的认可。新的建议涉及支持和指导研究人员的好处、定期评估患者-研究人员合作的必要性以及指定协调员在促进合作中的作用。工作组内的协议非常高,范围在 9.16 到 9.96 之间。
更新后的 EULAR PRP 参与建议更多地基于证据。与新增的 OAP 一起,它们应该成为研究人员和 PRP 的指南,并最终加强 PRP 在风湿病研究中的参与。